Cytokinetics Inc

2026. szept. 11. 20:08 UTC

Cytokinetics Inc shares are higher as analysts express positive sentiments, with Cantor Fitzgerald reiterating an Overweight rating and a price target of $112 from Truist.

2026. szept. 9. 19:36 UTC

Cytokinetics Inc shares are lower today amid rising crude oil prices and inflation concerns. The stock is currently below its 20-day moving average.

2026. szept. 8. 23:56 UTC

Cytokinetics Inc shares are higher in after-market trading, reflecting broader market sentiment following a strong jobs report and rising interest rate expectations.

2026. szept. 4. 23:51 UTC

Cytokinetics Inc shares are higher in after-market trading, reaching their highest cumulative return of the day, despite no specific news driving the move.

2026. szept. 3. 19:26 UTC

Cytokinetics Inc is trading higher as it announces participation in investor conferences and highlights an upcoming Supplemental New Drug Application for aficamten.

2026. szept. 2. 23:16 UTC

Cytokinetics Inc shares are trading lower after-market following its investor conference announcements, with Ionis Pharmaceuticals' decline possibly impacting sentiment in the sector.

2026. szept. 1. 20:09 UTC

Cytokinetics Inc shares are higher as Truist and H.C. Wainwright reaffirm Buy ratings, citing positive momentum and potential from recent ESC conference insights.

2026. aug. 31. 23:01 UTC

Cytokinetics Inc shares are lower in after-market trading amid broader market declines. Concerns over potential interest rate hikes may be influencing the downward trend.

2026. aug. 28. 22:01 UTC

Cytokinetics Inc shares are higher after announcing positive Phase 3 trial results for aficamten at the European Society of Cardiology Congress.

2026. aug. 26. 20:08 UTC

Cytokinetics shares advance amid social media discussions of a $100 price target, reflecting gains since Tuesday's close despite mixed U.S. market performance.

2026. aug. 14. 19:26 UTC

Cytokinetics shares are higher as H.C. Wainwright maintains a Buy rating and Barclays raises its price target to $110 amid strong sales momentum.

2026. aug. 13. 23:21 UTC

Cytokinetics Inc shares are higher in after-market trading, recovering from three consecutive lower sessions, though still below the 20-day moving average.

2026. aug. 12. 19:46 UTC

Cytokinetics Inc shares are lower today, continuing a decline since Tuesday's close. No specific news was identified to explain the movement.

2026. aug. 11. 19:11 UTC

Cytokinetics Inc shares declined as CEO Robert I. Blum sold 7,500 shares at $76.76, raising investor concerns about executive confidence in the company.

2026. aug. 10. 19:46 UTC

Cytokinetics shares rise as Truist upgrades rating and raises price target to $112, while Citizens increases its target to $110 following strong Q2 results.

2026. aug. 8. 00:01 UTC

Cytokinetics Inc shares are higher in after-market trading, recovering from earlier declines. The stock remains below its 20-day moving average.

2026. aug. 7. 22:51 UTC

Cytokinetics shares are rising in after-market trading, recovering from earlier session lows amid positive sentiment in US equities and mixed labor data.

2026. aug. 6. 23:21 UTC

Cytokinetics reports Q2 2026 net loss of $198.8 million, better than expected. Shares are higher in after-market trading amid positive sentiment.

2026. aug. 5. 20:06 UTC

Cytokinetics Inc shares are higher amid positive market sentiment and easing crude oil prices, despite a shift from recent daily closing trends.

2026. aug. 4. 23:01 UTC

Cytokinetics Inc is higher in after-market trading, gaining since Tuesday's close, though still below its 20-day moving average with no specific news identified.

2026. aug. 3. 19:36 UTC

Cytokinetics Inc shares are lower amid broader market trends influenced by geopolitical developments. Earlier in the session, shares pulled back from a session high.

2026. júl. 31. 20:02 UTC

Cytokinetics Inc is lower today amid a broader decline in the Biotechnology sub-sector, reversing a trend of higher daily closes since Thursday.

2026. júl. 30. 18:46 UTC

Cytokinetics receives UK marketing authorization for MYQORZO, a treatment for obstructive hypertrophic cardiomyopathy. Shares are trading higher amid positive market sentiment.

2026. júl. 29. 20:41 UTC

Cytokinetics Inc shares are lower in after-market hours, influenced by a broader market decline amid rising crude oil prices and anticipation of the Fed's policy announcement.

2026. júl. 28. 19:06 UTC

Cytokinetics shares are lower amid investor concerns over CEO Robert I. Blum's recent stock option exercise and sale, reported earlier today.

2026. júl. 27. 19:56 UTC

Cytokinetics Inc shares are lower, continuing a recent decline, amid social media discussions of a $103 price target and anticipated Myqorzo earnings in 2026.

2026. júl. 24. 23:46 UTC

Cytokinetics Inc shares are lower in after-market hours, continuing recent weakness after three consecutive daily declines. No specific news was identified for the move.

2026. júl. 22. 23:16 UTC

Cytokinetics Inc shares are lower in after-market hours amid broader market weakness, with no specific news identified to explain the decline.

2026. júl. 21. 18:16 UTC

Cytokinetics Inc is trading higher, with no specific news identified. The stock has gained since Monday amid rising commodity prices, particularly copper and oil.

2026. júl. 20. 19:22 UTC

Cytokinetics shares are lower amid declines in the Biotechnology sector. Myqorzo revenue expectations exceed consensus, with a long-term projection of $1.67 billion by 2030.